Notícias e Atividades da Astria Therapeutics

Astria Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Astria Therapeutics é uma empresa listada sob o símbolo ATXS (US).

Veja o organograma con seus 19 executivos principais

Biografias mais buscadas da Astria Therapeutics

• Jill Milne, Director and Chief Executive Officer
• Jonathan Violin, Director
• Hugh Cole, Director

Criar um alerta
para seguir os movimentos de executivos da Astria Therapeutics.

Astria Therapeutics possui 1.833 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Paul Meister - Chairman of the Board da Amneal Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Astria Therapeutics

• Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Astria Therapeutics
• Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference | Astria Therapeutics
• Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Astria Therapeutics
• Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema | Astria Therapeutics
• Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress | Astria Therapeutics
• Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Astria Therapeutics
• Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference | Astria Therapeutics
• Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session | Astria Therapeutics
• Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis | Astria Therapeutics
• Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE | Astria Therapeutics
• View more press releases Close

Redes sociais sobre Astria Therapeutics

• Astria Therapeutics na Wikipedia, Google News e Yahoo Finance
• Astria Therapeutics na LinkedIn, Twitter e YouTube